http://www.medpagetoday.com
Daniel Von Hoff, M.D., of the Scottsdale Clinical Research Institute in Arizona
SAN DIEGO, April 15 -- Eight of nine patients with metastatic basal cell carcinoma had durable clinical benefit with minimal toxicity when treated with an investigational compound that inhibits signaling in the Hedgehog pathway.
The spokesperson said, 'GDC-0499..."IT IS GDC-0449' BY GENENTECH LABS. DR. ERVIN EPSTEIN IN OAKLAND, CA IS ALSO WORKING WITH DR. VON HOFF ON THIS. I KNOW, I WAS SUPPOSED TO BE ONE OF THE FIRST PATEINTS. I HAVE GORLIN-GOLTZ SYNDROME. THOUSANDS OF BASAL CELL CARCINOMA'S. USING EFUDEX WAS HORRIFIC AND BURNED MY SKIN
giacomoxyz12 1 year ago